Inside the Alzheimer’s Drug Pipeline: What New Clinical Trials Mean for the Future | Dr. Jeffrey Cummings

Exciting advances in understanding Alzheimer’s biology, genetics, and biomarkers are driving new medicines, devices, and prevention strategies. In 2025 alone, 182 clinical trials evaluated 138 novel drugs for Alzheimer’s disease. In this episode, leading expert Dr. Jeffrey Cummings from the University of Nevada Las Vegas shares an insider’s look at the rapidly evolving Alzheimer’s treatment pipeline and what today’s clinical trials mean for the future. We also extend our gratitude to the clinical trial participants and families whose involvement makes this critical research possible